Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Kletting, Peter ^a   Maaß, Christian ^b   Reske, Sven ^a   Beer, Ambros J ^a   Glatting, Gerhard ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD66 ANTIBODY Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; YTTRIUM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BINDING SITE; BLOOD OXYGEN TENSION; BLOOD RADIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; ISOTOPE LABELING; MATHEMATICAL MODEL; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PREDICTION; PROBABILITY; PROTEIN BINDING; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; LEUKEMIA; TIME FACTOR;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL ADHESION MOLECULES; HUMANS; ISOTOPE LABELING; LEUKEMIA; MODELS, BIOLOGICAL; RADIOIMMUNOTHERAPY; TIME FACTORS; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 84930216506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127934     Document Type: Article

References (29)

1. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011; 3(3):349-70. doi: 10.2217/imt.10.114 PubMed PMID: 21395378; PubMed Central PMCID: PMC3123828.
2. Abutalib S.A., Tallman M.S. Monoclonal Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Pharm Biotechnol. 2006; 7:343-69. PMID: 17076651
3. Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske SN, et al. Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med. 2010; 51(3):484-91. doi: 10.2967/jnumed.109.067546 PMID: 20150257
4. Schulz A, Glatting G, Hoenig M, Schuetz C, Gatz S, Grewendorf S, et al. Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. Blood. 2011; 117(17):4642-50. doi: 10.1182/blood-2010-06-284349 PubMed PMID: 21325170.
5. Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, et al. 188Re- or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005; 130(4):604-13. PMID: 16098076
6. Kletting P, Kiryakos H, Reske SN, Glatting G. Analysing saturable antibody binding based on serum data and pharmacokinetic modelling. Phys Med Biol. 2011; 56(1):73-86. doi: 10.1088/0031-9155/56/1/005 PMID: 21119226
7. Glatting G, Reske SN. Determination of the immunoreactivity of radiolabeled monoclonal antibodies: A theoretical analysis. Cancer Biother Radiopharm. 2006; 21(1):15-21. PubMed PMID: 16480327.
8. 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. British journal of haematology. 2005; 130(4):604-13. doi: 10.1111/j.1365-2141.2005.05663.x PubMed PMID: 16098076.
9. Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Buck AK, et al. Internal radionuclide therapy: The UlmDos software for treatment planning. Med Phys. 2005; 32(7):2399-405. PMID: 16121597
10. Kaufman EN, Jain RK. Effect of Bivalent Interaction upon Apparent Antibody Affinity: Experimental Confirmation of Theory Using Fluorescence Photobleaching and Implications for Antibody Binding Assays. Cancer Res. 1992; 52(15):4157-67. PMID: 1638531
11. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003; 63(6):1288-96. Epub 2003/03/22. PubMed PMID: 12649189.
12. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, Foon KA, Reynolds JC, et al. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res. 1987; 47(12):3328-36. PMID: 3581071
13. Donohue DM, Reiff RH, Hanson ML, Betson Y, Finch CA. Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. J Clin Invest. 1958; 37(11):1571-6. Epub 1958/11/01. doi: 10.1172/JCI103750 PubMed PMID: 13587667; PubMed Central PMCID: PMC1062840.
14. Peters AM, Saverymuttu SH, Bell RN, Lavender JP. Quantification of the distribution of the marginating granulocyte pool in man. Scandinavian journal of haematology. 1985; 34(2):111-20. Epub 1985/02/01. PubMed PMID: 3975568.
15. Harris A, Kamishima T, Hao HY, Kato F, Omatsu T, Onodera Y, et al. Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters. European journal of radiology. 2010; 75(1):e97-101. doi: 10.1016/j.ejrad.2009.08.013 PubMed PMID: 19775843.
16. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005; 11(12):1481-93. PubMed PMID: 16315293.
17. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism. 1998; 47(4):484-92. PMID: 9550550
18. Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Buck AK, et al. Internal radionuclide therapy: The ULMDOS software for treatment planning. Med Phys. 2005; 32(7):2399. doi: 10.1118/1.1945348 PMID: 16121597
19. 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2003; 30(5):667-73. doi: 10.1007/s00259-002-1106-9 PubMed PMID: 12599012.
20. Kletting P, Glatting G. Model selection and inference in pharmacokinetics: The corrected Akaike information criterion and the F-test. Z Med Phys. 2009; 19(3):200-6. PMID: 19761098
21. Kletting P, Schimmel S, Kestler HA, Hanscheid H, Luster M, Fernandez M, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013; 40 (10):102504. Epub 2013/10/05. doi: 10.1118/1.4820367 PubMed PMID: 24089925.
22. Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, et al. In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging. 2009; 36(9):1443-52. doi: 10.1007/s00259-009-1120-2 PMID: 19350237
23. Elghetany MT. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis. 2002; 28(2):260-74. PMID: 12064921
24. Philips K. JS, McCarty O. Measurement of Single Cell Refractive Index, Dry Mass, Volume, and Density Using a Transillumination Microsope. Phys Rev Lett. 2012; 109(11).
25. Kletting P, Bunjes D, Luster M, Reske SN, Glatting G. Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Med Phys. 2011; 38(5):2572-8. PMID: 21776793
26. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ, 3rd. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Res. 2006; 5(6):1550-8. PMID: 16818514
27. Minarik D, Sjogreen-Gleisner K, Linden O, Wingardh K, Tennvall J, Strand SE, et al. 90Y Bremsstrah-lung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2010; 51(12):1974-8. PubMed PMID: 21078799.
28. Houston AS, Sampson WF, Macleod MA. A compartmental model for the distribution of 113mIn-DTPA and 99mTc-(Sn)DTPA in man following intravenous injection. Int J Nucl Med Biol. 1979; 6(2):85-95. PMID: 478771
29. rd Annual Congress of the European-Association-of-Nuclear-Medicine; 2010; Wien: SPRINGER, 233 SPRING ST, NEW YORK, NY 10013 USA.